C4 Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for C4 Therapeutics (CCCC).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

11Buy

Consensus RatingBuy# Analysts11Avg. Consensus PT$12Upside to Avg. PT+271.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	JP Morgan	Anupam Rama	Initiate	Overweight	$10
Jun 1, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$7→$12
Feb 27, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$5→$7
Feb 23, 2026	Brookline Capital	Leah Rush	PT Raise	Buy	$20→$30
Dec 17, 2025	Barclays	Etzer Darout	PT Cut	Overweight	$10→$5
Dec 2, 2025	TD Cowen	Tyler Van Buren	Initiate	Buy	—
Sep 23, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$5→$10
Sep 23, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$8→$10
Sep 22, 2025	Stephens & Co.	Sudan Loganathan	Maintained	Overweight	$6
Sep 17, 2025	Barclays	Etzer Darout	Initiate	Overweight	$8
Sep 15, 2025	Stephens & Co.	Sudan Loganathan	Upgrade	Equal-Weight→Overweight	$3→$6
Sep 4, 2025	Guggenheim	Brad Canino	Initiate	Buy	$8
Dec 19, 2024	Wells Fargo	Derek Archila	Upgrade	Equal-Weight→Overweight	$8→$12
Nov 18, 2024	Stephens & Co.	Sudan Loganathan	Initiate	Equal-Weight	$4
Aug 6, 2024	BMO Capital	Etzer Darout	Maintained	Outperform	$20
May 9, 2024	Wells Fargo	Derek Archila	PT Raise	Equal-Weight	$7→$8
May 9, 2024	Stifel	Bradley Canino	PT Raise	Buy	$13→$14
Feb 26, 2024	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$1→$8
Feb 23, 2024	Stifel	Bradley Canino	PT Raise	Buy	$12→$13
Jan 29, 2024	JP Morgan	Eric Joseph	Upgrade	Underweight→Neutral	$6

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and raises the price target from $7 to $12.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $7.

Benzinga Newsdesk

PRO
Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

Brookline Capital analyst Leah Rush maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $20 to $30.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.

Benzinga Newsdesk

This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

Avi Kapoor

C4 Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

C4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

PRO
Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

PRO
Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

PRO
Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

PRO
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

People Also Watch

People Also Watch

C4 Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

C4 Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

PROEvercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

PROBarclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

PROBrookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

PROBarclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

People Also Watch

People Also Watch

PRO
JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

PRO
Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12

PRO
Barclays Maintains Overweight on C4 Therapeutics, Raises Price Target to $7

PRO
Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30

PRO
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5